CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition ...
Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn ...